Stephen L. Eck - 15 Feb 2025 Form 4 Insider Report for MACROGENICS INC (MGNX)

Reporting relationship: Chief Medical Officer
Issuer ticker: MGNX
Reported as of: 15 Feb 2025
Net transaction value: -$12,652
SEC form: 4
Accepted by SEC: 19 Feb 2025, 16:20:46 UTC
Prior SEC filing: 11 Feb 2025
Source filing: View source filing
Reporting owner signature: Beth A. Smith, Attorney-in-fact

Key filing fact

Stephen L. Eck filed Form 4 for MACROGENICS INC (MGNX) on 19 Feb 2025.

Key facts

This page summarizes Stephen L. Eck's Form 4 filing for MACROGENICS INC (MGNX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 16:20.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: -$12,652.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGNX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +16,665
Change %: +94%
Price: $0.000000
Shares after: 34,319
Date: 15 Feb 2025
Ownership: Direct
Footnotes: F1

MGNX transaction

Common Stock

Tax liability

Transaction value: $12,652
Shares: -4,942
Change %: -14%
Price: $2.56
Shares after: 29,377
Date: 15 Feb 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGNX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -16,665
Change %: -50%
Price: $0.000000
Shares after: 16,665
Date: 15 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,665
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.